论文部分内容阅读
目的:探讨重组人脑利钠肽(rhBNP)对急性心力衰竭患者血浆半乳糖凝集素-3(Gal-3)、内皮素-1(ET-1)和胱抑素C(CysC)及心功能的影响。方法:将126例急性心力衰竭患者随机分为rhBNP组和对照组,每组各63例。rhBNP组在传统抗心力衰竭治疗基础上应用冻干rhBNP治疗,对照组在传统抗心力衰竭治疗基础上应用多巴酚丁胺治疗。观察2组患者治疗前后血浆Gal-3、ET-1、CysC水平、心功能参数变化情况、临床疗效及药物不良反应情况。结果:治疗72h后,rhBNP组心功能改善的总有效率显著高于对照组(88.89%vs.68.25%,P<0.05);2组血浆Gal-3、ET-1、CysC水平均有下降,但rhBNP组较对照组下降更显著(P<0.05)。rhBNP组左室射血分数(LVEF)、左室舒张末内径(LVEDD)治疗后均较治疗前显著改善,且改善程度优于对照组(P<0.05)。结论:rhBNP治疗可有效降低急性心力衰竭患者血浆Gal-3、ET-1和CysC水平,明显改善心功能,具有重要的临床应用价值。
Objective: To investigate the effects of recombinant human brain natriuretic peptide (rhBNP) on the expression of plasma Gal-3, ET-1 and cystatin C (CysC) and cardiac function in patients with acute heart failure Impact. Methods: 126 patients with acute heart failure were randomly divided into rhBNP group and control group, 63 cases in each group. The rhBNP group was treated with freeze-dried rhBNP on the basis of traditional anti-heart failure treatment, while the control group was treated with dobutamine on the basis of traditional anti-heart failure treatment. Plasma Gal-3, ET-1, CysC levels, cardiac function parameters, clinical efficacy and adverse drug reactions were observed before and after treatment in two groups. Results: After 72 hours of treatment, the total effective rate of heart function improvement in rhBNP group was significantly higher than that in control group (88.89% vs.68.25%, P <0.05). Plasma Gal-3, ET-1 and CysC levels were decreased in both groups However, the rhBNP group decreased more significantly than the control group (P <0.05). The left ventricular ejection fraction (LVEF) and left ventricular end diastolic diameter (LVEDD) in rhBNP group were significantly improved after treatment compared with before treatment, and the improvement was better than that of the control group (P <0.05). Conclusion: rhBNP treatment can effectively reduce the levels of plasma Gal-3, ET-1 and CysC in patients with acute heart failure and improve cardiac function. It has important clinical value.